Long-Term Survival Achieved in Stage III Melanoma with Pre-Surgery Immunotherapy

A machine learning model reveals expansive downregulation of ligand-receptor interactions that enhance lymphocyte infiltration in melanoma with developed resistance to immune checkpoint blockade

Immune checkpoint blockade (ICB) is a promising cancer therapy; however, resistance frequently develops. To explore ICB resistance mechanisms, we develop Immunotherapy Resistance cell-cell Interaction Scanner (IRIS), a machine learning model aimed at identifying cell-type-specific tumor microenvironment ligand-receptor interactions relevant to ICB resistance. Applying IRIS to deconvolved transcriptomics data of the five largest melanoma ICB coho…

Long-term survival achieved in stage III melanoma with pre-surgery immunotherapy

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87% of patients with stage III melanoma remained alive, according to new results from a study led by researchers at The University of Texas MD Anderson Cancer Center.

Most patients with advanced melanoma remain disease-free 4 years after pre-surgical immunotherapy, study finds

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87% of patients with stage III melanoma remained alive, according to new results from a study led by researchers at The University of Texas MD Anderson Cancer Center.

The treatment of advanced melanoma: Current approaches and new challenges

In recent years, advances in melanoma treatment have renewed patient hope. This comprehensive review emphasizes the evolving treatment landscape, part…

PD-1 Receptor Deficiency Enhances CD30 T Cell Function in Melanoma

The authors demonstrated that PD-1 deficiency enhances the function of Treg cells through expression of a compensatory network of coinhibitory receptors. [Nature Immunology] Full Article